ArticleEndocrine2018
Associations of serum glucagon levels with glycemic variability in type 1 diabetes with different disease durations.
Article in Endocrine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts.Journal of diabetes science and technology · 2022Trial
- Comparative Evaluation of Responsiveness of Insulin Counter-Regulatory Hormones and Insulin Resistance to Hypoglycemia in Newly Diagnosed Type 1 Diabetes Mellitus Man.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Glucagon receptor activation contributes to the development of kidney injury.American journal of physiology. Renal physiology · 2024Article
- Advances in clinical research on glucagon.Diabetology international · 2024Review
- Polyester Nanoparticles with Controlled Topography for Peroral Drug Delivery Using Insulin as a Model Protein.ACS nano · 2024Article
- Abnormal late postprandial glucagon response in type 1 diabetes is a function of differences in stimulated C-peptide concentrations.Frontiers in endocrinology · 2024Article
- Association between hemoglobin glycation index and diabetic kidney disease in type 2 diabetes mellitus in China: A cross- sectional inpatient study.Frontiers in endocrinology · 2023Article
- Association between hemoglobin glycation index and non-alcoholic fatty liver disease.Frontiers in endocrinology · 2023Article
- Association of sleep quality with glycemic variability assessed by flash glucose monitoring in patients with type 2 diabetes.Diabetology & metabolic syndrome · 2021Article
- HbAJournal of clinical and translational hepatology · 2021Article
- The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Review
- Correlation Between Hemoglobin Glycosylation Index and Nerve Conduction Velocity in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Pasireotide-induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment.Clinical case reports · 2020Article
- Molecular Mechanisms of Glucose Fluctuations on Diabetic Complications.Frontiers in endocrinology · 2019Review
- Association between Hemoglobin Glycation Index and NAFLD in Chinese Nondiabetic Individuals.Canadian journal of gastroenterology & hepatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlucagon has been recognized as a pivotal factor implicated in the pathophysiology ofdiabetes. The purpose of this study is to investigate the dynamic secretion levels of serum glucagon (GLA) in patients with type 1 diabetes mellitus (T1DM) with different courses of disease, and to analyze its correlation with blood glucose fluctuation.
methodsThis observational study included 55 T1DM patients and divided into 3 groups according to the courses of disease. Group 1(the disease duration <1 year), Group 2(1≤the disease durations≤5), 3(the disease durations >5 years). All patients underwent a 100g standard steamed buns meal test,measuring the levels of serum glucose, glucagon, insulin, C-peptide in different points of time, and 48 of the total patients used continuous glucose monitoring system (CGMS) to monitor blood glucose.
resultsThe fasting glucagon level in Group 1 was significantly higher than it in Group 2. Furthermore, the GLA1h, the GLA3h and the AUCGLA0-3h in Group 1 were greatly larger than those in Group 3. Referring to glycemic variability, the LBGI, AUC of hypoglycemia, the percentage of hypoglycemia time andthe times of nocturnal hypoglycemia in Group 1 were significantly lower than those in Group 3. Moreover,the fasting glucagon level was the independent factors to SD and MAGE. The AUCGLA0-3h were negatively correlated with MODD, LBGI, GRADE-hypo and AUC of nocturnal hypoglycemia.
conclusionsIt is concluded that glucagon secretory function impairs with duration of type 1 diabetes extended and correlates to glycemic fluctuation, especially hypoglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.